These mutations lead to an altered distribution of iRhom2 inskin and dysregulated EGFR signaling [58].The underlying mechanism was related to the mutations activating iRhom2 whichleads to increased ADAM17 maturation and activity in epidermal keratinocytesfrom TOC patients, which in turn increases shedding of TNFα, AR, TGFα andHB-EGF and enhances EGFR phosphorylation [57].Consistently, both iRhom1 and iRhom2 expression was found to be enhanced inall histological cervical carcinoma types. Here, EGFR is linked to cervical carcinoma.